Check out our posters at the American Association for Cancer Research 2025:
Abstract #3011 – Monday April 28th, 2-5PM Experimental & Molecular Therapeutics, Poster section 20, Board 12 – “Novel CDK12 inhibitors with preclinical anti-tumor activity and best-in-class profile on HER2 low breast cancer patient samples” – Download PDF here
Abstract #4724, Tuesday April 29th, 9-12PM, Clinical Research, Poster section 34, Board 22 – “Evaluating immunotherapy and combination therapy efficacy in kidney cancer using a multicellular 3D immune-microtumor model” – Download PDF here
Abstract #3917 – Tuesday April 29th, 9-12PM, Tumour Biology, Poster section 4, Board 10 – “A functional precision medicine assay for immunotherapy and combination therapy testing in liver and pancreatic cancers (PEAR-PAL)” – Download PDF here
Or check out our precision medicine workflow poster – Download PDF here
Check out our poster at the San Antonio Breast Cancer Symposium 2024 to learn more about how Pear Bio is advancing precision oncology through our PEAR-TNBC clinical trial.
Kidney immune-microtumor models and combination immunotherapy testing.
//
We are delighted to announce that we have recruited our first breast cancer patient to the PEAR-TNBC trial. The patient underwent a biopsy last week at St. Bartholomew’s NHS Trust, and we have been busy culturing and treating the breast cancer cells in the lab.
//
The Pear Bio Platform allows us to grow and treat multiple microtumors in parallel so that we can determine which drugs are likely to be effective. Unlike other tests that measure a biomarker, we directly test different drugs in parallel on an individual patient tumor sample.
//
PEAR-TNBC is a multi-centre, observational study for patients with newly diagnosed Triple Negative Breast Cancer who are about to start chemotherapy as their first treatment (“neoadjuvant chemotherapy”). Patients receive standard treatment, and we treat the tumor samples in the lab with the same chemotherapy as the treating team has chosen to use. The primary endpoint of the trial is to see how accurately the patient responses to treatment can be predicted by the Pear Bio test.
//
PEAR-TNBC is currently open at St. Bartholomew’s, and will open in other centers across the UK in 2022 to recruit 30 patients with TNBC. We have a range of trials for other cancer types under active development.
//
Pear Bio has added immuno-oncology capabilities to our precision medicine platform. We can now track immune cell infiltration into patient-derived 3D tumor cultures using time-lapsed 3D microscopy.